Urology
Volume 76, Issue 3 , Pages 765.e1-765.e7 , September 2010

Meta-analysis of Association Between TP53 Arg72Pro Polymorphism and Bladder Cancer Risk

  • De-Ke Jiang

      Affiliations

    • State Key Laboratory of Genetic Engineering, Fudan University, Shanghai, China
    • ,
  • Wei-Hua Ren

      Affiliations

    • State Key Laboratory of Genetic Engineering, Fudan University, Shanghai, China
    • ,
  • Lei Yao

      Affiliations

    • State Key Laboratory of Genetic Engineering, Fudan University, Shanghai, China
    • ,
  • Wen-Zhang Wang

      Affiliations

    • State Key Laboratory of Genetic Engineering, Fudan University, Shanghai, China
    • ,
  • Bo Peng

      Affiliations

    • State Key Laboratory of Genetic Engineering, Fudan University, Shanghai, China
    • ,
  • Long Yu

      Affiliations

    • State Key Laboratory of Genetic Engineering, Fudan University, Shanghai, China
    • Institute of Biomedical Science, Fudan University, Shanghai, China
    • Corresponding Author InformationReprint requests: Long Yu, M.D., Ph.D., State Key Laboratory of Genetic Engineering, Fudan University, 220 Handan Road, Shanghai 200433 China

Received 20 April 2010 ,Accepted 26 April 2010.

References 

  1. Grasso M. Bladder cancer: a major public health issue. Eur Urol Suppl. 2008;7:510–515
  2. Colombel M, Soloway M, Akaza H, et al. Epidemiology, staging, grading, and risk stratification of bladder cancer. Eur Urol Suppl. 2008;7:618–626
  3. Volanis D, Kadiyska T, Galanis A, et al. Environmental factors and genetic susceptibility promote urinary bladder cancer. Toxicol Lett. 2010;193:131–137
  4. Guey LT, Garcia-Closas M, Murta-Nascimento C, et al. Genetic susceptibility to distinct bladder cancer subphenotypes. Eur Urol. 2010;57:283–292
  5. Levine AJ, Finlay CA, Hinds PW. p53 is a tumor suppressor gene. Cell. 2004;116:S67–S69
  6. Hrstka R, Coates PJ, Vojtesek B. Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. J Cell Mol Med. 2009;13:440–453
  7. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9:95–107
  8. Matlashewski GJ, Tuck S, Pim D, et al. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol. 1987;7:961–963
  9. Thomas M, Kalita A, Labrecque S, et al. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19:1092–1100
  10. Dumont P, Leu JI, Della Pietra AC, et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33:357–365
  11. Klug SJ, Ressing M, Koenig J, et al. TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol. 2009;10:772–784
  12. Yan L, Zhang D, Chen C, et al. TP53 Arg72Pro polymorphism and lung cancer risk: a meta-analysis. Int J Cancer. 2009;125:2903–2911
  13. Zhang Z, Wang M, Wu D, et al. p53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case-control studies. Breast Cancer Res Treat. 2010;120:509–517
  14. Zhou Y, Li N, Zhuang W, et al. p53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer. 2007;121:1481–1486
  15. Wu WJ, Kakehi Y, Habuchi T, et al. Allelic frequency of p53 gene codon 72 polymorphism in urologic cancers. Jpn J Cancer Res. 1995;86:730–736
  16. Biro E, Kalina I, Salagovic J, et al. p53 single nucleotide polymorphisms and bladder cancer. Neoplasma. 2000;47:303–306
  17. Chen WC, Tsai FJ, Wu JY, et al. Distributions of p53 codon 72 polymorphism in bladder cancer—proline form is prominent in invasive tumor. Urol Res. 2000;28:293–296
  18. Toruner GA, Ucar A, Tez M, et al. p53 codon 72 polymorphism in bladder cancer—no evidence of association with increased risk or invasiveness. Urol Res. 2001;29:393–395
  19. Soulitzis N, Sourvinos G, Dokianakis DN, et al. p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett. 2002;179:175–183
  20. Mabrouk I, Baccouche S, El-Abed R, et al. No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann NY Acad Sci. 2003;1010:764–770
  21. Kuroda Y, Tsukino H, Nakao H, et al. p53 codon 72 polymorphism and urothelial cancer risk. Cancer Lett. 2003;189:77–83
  22. Chung CJ, Huang CJ, Pu YS, et al. Polymorphisms in cell cycle regulatory genes, urinary arsenic profile and urothelial carcinoma. Toxicol Appl Pharmacol. 2008;232:203–209
  23. Horikawa Y, Nadaoka J, Saito M, et al. Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncol Rep. 2008;20:49–55
  24. Ye Y, Yang H, Grossman HB, et al. Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer. 2008;112:2467–2474
  25. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–129
  26. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–748
  27. derSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188
  28. Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull. 1999;8:15–17
  29. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634
  30. Furihata M, Takeuchi T, Matsumoto M, et al. p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract. Clin Cancer Res. 2002;8:1192–1195
  31. Shinohara A, Sakano S, Hinoda Y, et al. Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy. Cancer Sci. 2009;100:2376–2382
  32. Lancaster JM, Brownlee HA, Wiseman RW, et al. p53 polymorphism in ovarian and bladder cancer. Lancet. 1995;346:182
  33. Berggren P, Hemminki K, Steineck G Stockholm Bladder Cancer Group. p53 intron 7 polymorphisms in urinary bladder cancer patients and controls. Mutagenesis. 2000;15:57–60
  34. Chen YC, Xu L, Guo YL, et al. Polymorphisms in GSTT1 and p53 and urinary transitional cell carcinoma in south-western Taiwan: a preliminary study. Biomarkers. 2004;9:386–394
  35. Chang CC, Hsieh YY, Tsai FJ, et al. The proline form of p53 codon 72 polymorphism is associated with endometriosis. Fertil Steril. 2002;77:43–45
  36. Wacholder S, Chanock S, Garcia-Closas M, et al. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004;96:434–442
  37. Mitchell AA, Cutler DJ, Chakravarti A. Undetected genotyping errors cause apparent overtransmission of common alleles in the transmission/disequilibrium test. Am J Hum Genet. 2003;72:598–610
  38. Hosking L, Lumsden S, Lewis K, et al. Detection of genotyping errors by Hardy-Weinberg equilibrium testing. Eur J Hum Genet. 2004;12:395–399
  39. Salanti G, Amountza G, Ntzani EE, et al. Hardy-Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet. 2005;13:840–848
  40. Trikalinos TA, Salanti G, Khoury MJ, et al. Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations. Am J Epidemiol. 2006;163:300–309

 This study was supported by the National 973 program of China (grant 2004CB518605), National 863 project of China (grant 2006AA020501), National Key Sci-Tech Special Project of China (grant 2008ZX10002-020), Project of the Shanghai Municipal Science and Technology Commission (grant 03dz14086), and National Natural Science Foundation of China (grants 30024001 and 30771188).

PII: S0090-4295(10)00613-8

doi: 10.1016/j.urology.2010.04.044

Urology
Volume 76, Issue 3 , Pages 765.e1-765.e7 , September 2010

Article Tools

* Image Usage & Resolution